Aleksandra M Wojtas, Eric B Dammer, Qi Guo, Lingyan Ping, Ananth Shantaraman, Duc M Duong, Luming Yin, Edward J Fox, Fatemeh Seifar, Edward B Lee, Erik C B Johnson, James J Lah, Allan I Levey, Yona Levites, Srikant Rangaraju, Todd E Golde, Nicholas T Seyfried
INTRODUCTION: Cerebrovascular dysfunction is a pathological hallmark of Alzheimer's disease (AD). Nevertheless, detecting cerebrovascular changes within bulk tissues has limited our ability to characterize proteomic alterations from less abundant cell types. METHODS: We conducted quantitative proteomics on bulk brain tissues and isolated cerebrovasculature from the same individuals, encompassing control (N = 28), progressive supranuclear palsy (PSP) (N = 18), and AD (N = 21) cases...
May 7, 2024: Alzheimer's & Dementia: the Journal of the Alzheimer's Association